Low-dose acetylsalicylic acid use and the risk of upper gastrointestinal bleeding: A meta-analysis of randomized clinical trials and observational studies

Canadian Journal of Gastroenterology

Volumn 27, Issue 3, 2013, Pages 159-167

  Valkhoff, Vera E ^a   Sturkenboom, Miriam C J M ^a   Hill, Catherine ^b   Van Zanten, Sander Veldhuyzen ^c   Kuipers, Ernst J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b OXFORD PHARMAGENESIS LTD   (United Kingdom)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Acetylsalicylic acid; Gastrointestinal bleeding; Gastrointestinal hemorrhage; Meta analysis; Peptic ulcer disease

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO; ANTITHROMBOCYTIC AGENT;

HUMAN; LOW DRUG DOSE; META ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; UPPER GASTROINTESTINAL BLEEDING; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DUODENUM DISEASE; ESOPHAGUS DISEASE; GASTROINTESTINAL HEMORRHAGE; RISK; STOMACH DISEASE;

ASPIRIN; CARDIOVASCULAR DISEASES; DUODENAL DISEASES; ESOPHAGEAL DISEASES; GASTROINTESTINAL HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; RISK; STOMACH DISEASES;

EID: 84876272891     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2013/596015     Document Type: Review

References (60)

1. Anderson JL, Adams CD, Antman EM, et al. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the management of patients with unstable angina/non-STelevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123:2022-60.
2. Baigent C, Sudlow C, Collins R, et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
3. Björklund L, Wallander MA, Johansson S, et al. Aspirin in cardiology - benefits and risks. Int J Clin Pract 2009;63:468-77.
4. Cea Soriano L, García Rodríguez LA. Risk of upper gastrointestinal bleeding in a cohort of new users of low-dose ASA for secondary prevention of cardiovascular outcomes. Front Pharmacol 2010;1:126-35.
5. Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: Epidemiology, prevention and treatment. Curr Med Res Opin 2007;23:163-73.
6. Slattery J, Warlow CP, Shorrock CJ, et al. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin - analysis of gastrointestinal bleeding during the UK-TIA trial. Gut 1995;37:509-11.
7. Sprigg ER, Fleming KM, Logan RFA. Is low dose aspirin use associated with iron deficiency anaemia? An analysis of data from the Health Survey for England 2006. Gut 2009;58(Suppl II):A91.
8. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: Meta-analysis. BMJ 2000;321:1183-7.
9. García Rodríguez LA, Hernández-Díaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: Systematic review of epidemiologic studies. Br J Clin Pharmacol 2001;52:563-71.
10. Hayden M, Pignone M, Phillips C, et al. Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:161-72.
11. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006;119:624-38.
12. Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: An overview of randomised controlled trials. Br J Clin Pharmacol 1993;35:219-26.
13. Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005;95:1218-22.
14. Stalnikowicz-Darvasi R. Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events. A critical analysis. J Clin Gastroenterol 1995;21:13-6.
15. Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 2002;162:2197-202.
16. Hawkey CJ. Non-steroidal anti-inflammatory drugs and peptic ulcers. BMJ 1990;300:278-84.
17. Dickinson JP, Prentice CR. Aspirin: Benefit and risk in thromboprophylaxis. QJM 1998;91:523-38.
18. Cappelleri JC, Lau J, Kupelnick B, et al. Efficacy and safety of different aspirin dosages on vascular diseases in high-risk patients. A metaregression analysis. Online J Curr Clin Trials 1995; Doc No 174.
19. Sudlow C. Cardiovascular disorders: Primary prevention. Clinical evidence. American College of Physicians-American Society of Internal Medicine, 5th edn. London: BMJ Publishing Group, 2001.
20. Lanas A, Wu P, Medin J, et al. Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. Clin Gastroenterol Hepatol 2011;9:762-8.
21. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989;321:129-35.
22. Diener HC, Forbes C, Riekkinen PJ, et al. European stroke prevention study 2: Efficacy and safety data. J Neurol Sci 1997;151:S41-S51.
23. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995;310:827-30.
24. Ibánez L, Vidal X, Vendrell L, et al. Upper gastrointestinal bleeding associated with antiplatelet drugs. Aliment Pharmacol Ther 2006;23:235-42.
25. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
26. Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:1075-8.
27. Laporte JR, Ibáñez L, Vidal X, et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: Newer versus older agents. Drug Saf 2004;27:411-20.
28. Farrell B, Godwin J, Richards S, et al. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: Final results. J Neurol Neurosurg Psychiatry 1991;54:1044-54.
29. Bjerre LM, LeLorier J. Expressing the magnitude of adverse effects in case-control studies: The number of patients needed to be treated for one additional patient to be harmed. BMJ 2000;320:503-6.
30. Sørensen HT, Mellemkjær L, Blot WJ, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000;95:2218-24.
31. Uppalapati SS, Boylan JD, Stoltzfus J. Risk factors involved in patients with bleeding peptic ulcers: A case-control study. Dig Dis Sci 2009;54:593-8.
32. Silagy CA, McNeil JJ, Donnan GA, et al. Adverse effects of low-dose aspirin in a healthy elderly population. Clin Pharmacol Ther 1993;54:84-9.
33. Bax L, Yu LM, Ikeda N, et al. Development and validation of MIX: Comprehensive free software for meta-analysis of causal research data. BMC Med Res Methodol 2006;6:50.
34. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
35. Lanas A, Bajador E, Serrano P, et al. Effects of nitrate and prophylactic aspirin on upper gastrointestinal bleeding: A retrospective case-control study. J Int Med Res 1998;26:120-8.
36. Santolaria S, Lanas A, Benito R, et al. Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users. Aliment Pharmacol Ther 1999;13:1511-8.
37. Kaufman DW, Kelly JP, Sheehan JE, et al. Nonsteroidal antiinflammatory drug use in relation to major upper gastrointestinal bleeding. Clin Pharmacol Ther 1993;53:485-94.
38. Lanas A, Bajador E, Serrano P, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal anti-inflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000;343:834-9.
39. Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996;348:1413-6.
40. Kaufman DW, Kelly JP, Wiholm BE, et al. The risk of acute major upper gastrointestinal bleeding among users of aspirin and ibuprofen at various levels of alcohol consumption. Am J Gastroenterol 1999;94:3189-96.
41. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998;351:233-41.
42. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000;355:1295-302.
43. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: A randomized controlled trial. JAMA 2008;300:2134-41.
44. de Abajo FJ, García Rodríguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol 2001;1:1.
45. Stack WA, Atherton JC, Hawkey GM, et al. Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment Pharmacol Ther 2002;16:497-506.
46. Lanas A, García Rodríguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclooxygenase- 2 inhibitors, traditional non-aspirin non-steroidal antiinflammatory drugs, aspirin and combinations. Gut 2006;55:1731-8.
47. Sakamoto C, Sugano K, Ota S, et al. Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal antiinflammatory drugs in Japan. Eur J Clin Pharmacol 2006;62:765-72.
48. Udd M, Miettinen P, Palmu A, et al. Analysis of the risk factors and their combinations in acute gastroduodenal ulcer bleeding: A case-control study. Scand J Gastroenterol 2007;42:1395-403.
49. Becker RC, Meade TW, Berger PB, et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th edn. Chest 2008;133:776S-814S.
50. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054.
51. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008;118:1894-909.
52. Sung JJ, Lau JY, Ching JY et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: A randomized trial. Ann Intern Med 2010;152:1-9.
53. García Rodríguez LA, Cea Soriano L, Johansson S. Increased risk of stroke after discontinuation of low-dose acetylsalicylic acid therapy: A UK primary care study. Cerebrovasc Dis 2010;29 Suppl 2:79.
54. García Rodríguez LA, Cea Soriano L, Hill C, et al. Increased risk of stroke after discontinuation of acetylsalicylic acid: A UK primary care study. Neurology 2011;76:740-6.
55. Yeomans N, Lanas A, Labenz J, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 2008;103:2465-73.
56. Scheiman J, Herlitz J, Agewall S, et al. Peptic ulcer prevention by esomeprazole 20 mg and 40 mg once daily in patients taking lowdose acetylsalicylic acid for secondary cardiovascular prevention. Gut 2010;59:A53.
57. Lewis HD Jr. Unstable angina: Status of aspirin and other forms of therapy. Circulation 1985;72:V155-60.
58. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ (Clin Res Ed) 1988;296:313-16.
59. Levy M. Aspirin use in patients with major upper gastrointestinal bleeding and peptic-ulcer disease. A report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center. N Engl J Med 1974;290:1158-62.
60. Levy M, Miller DR, Kaufman DW, et al. Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics. Arch Intern Med 1988;148:281-5.